论文部分内容阅读
目的探究乳腺癌新辅助治疗疗效的相关因素。方法回顾分析我院2012年2月-2012年12月58例接受新辅助治疗的乳腺癌患者,免疫组化法检测患者的雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)、人表皮生长因子受体(human epidermal growth factor receptor-2,HER-2)表达情况,讨论乳腺癌患者TNM分期、ER、PR、HER-2表达与月经状况、原发肿瘤大小对新辅助治疗疗效的相关性。结果统计显示TNM分期越早,病理完全缓解率愈高,ER阴性、PR阴性、HER-2低表达的患者化疗有效率高,差异有统计学意义(P<0.05),而月经状况、原发肿瘤大小对治疗的有效率差异无统计学意义(P>0.05)。结论 TNM分期越早,ER阴性、PR阴性、HER-2低表达的乳腺癌患者新辅助治疗的疗效更好,病理完全缓解率高。
Objective To explore the effect of neoadjuvant therapy on breast cancer. Methods A retrospective analysis of 58 patients with neoadjuvant breast cancer from February 2012 to December 2012 in our hospital was conducted. The expression of estrogen receptor (ER), progesterone receptor , PR) and HER-2 expression in breast cancer patients. The expressions of ER, PR, HER-2, Relevance of neoadjuvant therapy. The results showed that the earlier the TNM staging, the higher the pathological complete remission rate, the ER-negative, the PR-negative, the HER-2 low expression of chemotherapy in patients with high efficiency, the difference was statistically significant (P <0.05) There was no significant difference in the effective rate of tumor size between the two groups (P> 0.05). Conclusion The earlier stage of TNM staging, ER-negative, PR-negative, HER-2 low expression of breast cancer patients with neoadjuvant therapy better curative effect, high complete remission rate.